The Role of CardioSEAL and Starflex Devices in Atrial Defect Occlusion
1Department of Pediatrics, Division of Cardiology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada.
Current Interventional Cardiology Reports
|November 30, 2000
Summary
The CardioSEAL and Starflex devices effectively close atrial septal defects (ASDs) in over 90% of patients. This article details their development, implantation techniques, and clinical outcomes for these septal occluders.
Area of Science:
- Cardiovascular Medicine
- Medical Devices
- Interventional Cardiology
Background:
- Secundum atrial septal defects (ASDs) are common congenital heart conditions.
- Transcatheter device closure is an alternative to surgical repair for ASDs.
- Nitinol-based septal occluders offer minimally invasive treatment options.
Purpose of the Study:
- To review the development and design of CardioSEAL and Starflex septal occluders.
- To discuss the implantation technique for these devices.
- To present the clinical results of using these devices for ASD closure.
Main Methods:
- Review of device development and design principles.
- Description of the implantation procedure.
- Analysis of clinical outcomes from patient data.
Main Results:
- CardioSEAL and Starflex are self-expanding, double-umbrella septal occluders.
- The Starflex device features a self-centering mechanism.
- Successful clinical occlusion of ASDs is achieved in over 90% of patients.
Conclusions:
- These devices provide a high success rate for ASD closure.
- The article offers insights into the practical application and outcomes of these devices.
- Further evaluation of long-term results may be beneficial.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:15Aortic Regurgitation I: Introduction
IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...
01:25Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...